

November 2021

# Investment Sheet TOPADUR Pharma AG

Information about series C-2 up to CHF 22 M equity

## About TOPADUR Pharma AG

TOPADUR Pharma AG is a Swiss biopharmaceutical start-up based in Schlieren, Zurich. The company discovered and developed DualTOP™ technology platform consisting of new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. The DualTOP™ technology will promote healthy long life. TOPADUR Pharma AG was founded in 2015 by experienced scientists that combine several years of expertise in research and development in the pharmaceutical industry. The focus is the research and development of new, innovative drugs for aging-related diseases such as chronic wounds, diabetic retinopathy, colorectal cancer and hair loss. TOPADUR Pharma AG offers patients highly effective and safe products.

## Investment strategy

TOPADUR Pharma AG has a rich portfolio of drugs. The business strategy is to achieve an early partnership with globally operating pharmaceutical companies and thus to out-license the drug candidates. TOPADUR Pharma AG has already received several awards and is excellently positioned in the market. Thanks to the long-term business strategy approved by the Board of Trustees, the mature pipeline and the forthcoming IPO, TOPADUR Pharma AG investors can expect a significant return on investment.

## Financing strategy

Funds from the capital increase Series C-2 are mainly used for the development of the following products: wound healing (CHF 6-8 M); diabetic retinopathy (CHF 2-3 M); colorectal cancer (CHF 2-3 M); alopecia (CHF 1 M); further development of the pipeline (CHF 1-2 M) and IPO preparation (CHF 0.5 M).

## Exit strategy

IPO to Nasdaq stock exchange segment (2023) at estimated valuation > CHF 500 M.

## Development portfolio


The development portfolio consists of three products. Some of these are in the mature phase. All products are marketed in the form of out-licensing.

- **TOP-N53** wound healing in chronic diabetic foot wounds, finger wounds in systemic scleroderma (a rare disease indication)
- **TOP-M119** medical cosmetic, hair loss (out-licensing to development fund)
- **TOP-V122** diabetic retinopathy, colorectal cancer, lung fibrosis

## Further information

<b>Issuer</b>	TOPADUR Pharma AG
<b>Auditors</b>	KPMG, Zürich
<b>Custodian</b>	Zürcher Kantonalbank
<b>Inception</b>	March 10 <sup>th</sup> , 2015
<b>Company identification</b>	CHE 481.951.668
<b>Business year</b>	January 1 <sup>st</sup> – December 31 <sup>st</sup>
<b>Annual report</b>	annually per 31.3.
<b>Price p. share</b>	270.00 – 300.00 CHF
<b>Report</b>	Quarterly publication
<b>Special provisions</b>	Sale of shares (series C-2) as stated in the shareholder agreement until the expected IPO
<b>Expected pre-money valuation Ser-C2</b>	Approx. CHF 56.0 M (mid 2021)
<b>Expected IPO</b>	2023
<b>Minimum subscription</b>	CHF 150'000.00
<b>Subscription period</b>	Starting mid November 2021
<b>Allocation of shares</b>	Shares will be allocated when the next capital increase is completed (expected closing Q1 2022).

## Share price (history)



Outlook A: based on 50% goal achievement  
 Outlook B: based on 100% goal achievement  
 Historical returns and financial market scenarios are no guarantee of current and future results.

### Product pipeline

**TOP-N53:** This is the first drug candidate selected in 2015 from a series of dual-mode of action drugs. The drug increases local microcirculation and induces the formation of new blood vessels resulting in increased oxygen and nutrient supply to the tissue, where the drug is applied. TOP-N53 has demonstrated unprecedented potency and efficacy in animal models of wound healing, including diabetic mice wound healing models. The drug is very well tolerated and does not show side effects below 2 mg/kg in rats and dogs. Daily doses are predicted to be below 1 µg/kg. This drug candidate entered Phase 1 clinical trial in September 2020 as a new promising drug to enable healing of chronic foot ulcers (DFU) in diabetic patients. The study met the primary and secondary endpoints demonstrating a favorable safety and tolerability profile in all the healthy subjects recruited. The results on skin blood flow, an exploratory endpoint, measured by Laser Speckle Contrast Imaging (LSCI) are very encouraging. The overall efficacy profile of TOP-N53 showed a dose-dependent increase in blood flow that lasted 24h in the highest two dose groups, at single-digit microgram range.

There is a huge medical need to help 50 M patients in intensive care situations every year. More than 1 M foot amputations are resulting from this illness for which no effective treatment exists. In order to get faster to the market TOPADUR applied for orphan drug designation for digital ulcers in systemic sclerosis patients that was granted by EMA in October 2021. We intend to get proof-of-concept for wound healing in these patients in 2022.

**TOP-M119:** This is a second-generation dual-mode of action drug, which shows very potent hair growth promotion activity in animal models of alopecia. The compound is in development for treatment of alopecia and evaluated for chemotherapy induced hair loss. For both indications promising preclinical proof-of-concept data were generated. A special fund (current valuation CHF 50 M), of which TOPADUR will own 60-70% is

currently being raised to develop this product till clinical phase 2 proof-of-concept.


**TOP-V122:** This is the strongest dual-mode active ingredient of the second generation from a large collection of our highly active molecules. The main indications for this drug candidate are eye diseases and the prevention of colon cancer. Our first indication for this drug candidate is diabetic retinopathy, an indication where the medical demand is high. Promising preclinical proof-of-concept data exist in both indications. Given the high and unique effectiveness of this product, it has considerable potential for additional indications, such as lung fibrosis and pulmonary arterial hypertension. We expect TOP-V122 to have disease-modifying effects, based on the angiogenetic activity when applied locally to lung tissues. An interesting entry patient population could be the treatment of refractory group of patients, high-risk patients and candidates for lung transplantations. The expected increased drug efficacy over SoC would however have a much higher therapeutic treatment potential. Partnering discussions with leading companies in that field are ongoing.

### Awards from TOPADUR Pharma AG


- Co-Winner Pitching Battle CEO Day 2015
- Finalist Swiss Innovation Challenge 2015
- Winner Venture Leaders Life Science 2016
- Top 100 Schweizer Startups 2016
- CTI-Label-Unternehmen 2016
- Winner IMD Startup 2016
- Top 100 Swiss Startups 2017
- Winner Swiss Innovation Challenge 2017
- Winner Venture Leaders China 2018
- Top 100 Schweizer Startups 2018
- Winner SEF Award 2018
- Winner ED Dong Sheng Cup 2018
- Top 100 Schweizer Startups 2020

### The decision makers of TOPADUR Pharma AG

#### Board of Directors



#### Leadership Team



**Contact:**

TOPADUR Pharma AG  
Dr. Reto Naef, CEO  
Grabenstrasse 11A  
CH-8952 Schlieren

T +41 44 755 44 66  
M + 41 79 204 77 05  
[info@topadur.com](mailto:info@topadur.com)  
[www.topadur.com](http://www.topadur.com)



Please don't hesitate to contact us if you might have any further questions.

---

**DISCLAIMER**

This document was created by TOPADUR Pharma AG (hereinafter "TOPADUR") carefully and to the best of its knowledge and belief. However, TOPADUR gives no guarantee with regard to its content and completeness and does not accept any liability for losses resulting from the use of this information. The opinions expressed in this document are those of TOPADUR at the time of writing and are subject to change at any time and without notice. The following risks and uncertainties could influence the accuracy of this document: For example, the future financial position, capital requirements, the progress of research and development, the completion and success of clinical trials for the candidate drugs, current and future cooperation partners, as well as future developments, trends and conditions in the Industry in which TOPADUR operates. Should one or more of these risks or uncertainties arise or should underlying assumptions prove to be incorrect, the actual results and figures may differ materially from those stated. Unless otherwise noted, all figures are unaudited. The document is for informational purposes only and is for the exclusive use of the recipient. It does not constitute an offer or a recommendation to subscribe or otherwise acquire claims to TOPADUR and does not release the recipient from making his own assessment. In particular, the recipient is advised to check the information with regard to the compatibility with his own circumstances, if necessary with the help of a consultant. The only thing that is decisive for the subscription of claims is the applicable prospectus as well as the statutes and regulations of TOPADUR. This document may not be reproduced in whole or in part without the written consent of TOPADUR. It is expressly aimed only at pension funds and other tax-exempt institutions based in Switzerland that serves occupational pension purposes according to their purpose, as well as at people who manage pension funds and are supervised by FINMA. Every investment involves risks, especially those of fluctuations in value and income. Historical returns and financial market scenarios are no guarantee of current and future results. Regarding performance: There can be no guarantee that the performance of competing companies and/ or the benchmark index will be achieved or exceeded. TOPADUR is the issuer of securities and/or loans of any kind (including hybrids, etc.). Further information and documents are available on the website [www.topadur.com](http://www.topadur.com) and can be viewed at any time. The current annual report or factsheets can be obtained free of charge from TOPADUR on request.